Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Intelligent Health aim to get the whole community active by providing games and incentives such as ''beat the street''. By providing schools and communities with friendly competition to walk and cycle more by tapping their cards on ''beat boxes'', and with prizes and league tables on offer, Intelligent health are bringing communities together.
days to go:
Expired
investment:
£700,000
Findr aims to automate the creation of business partnerships by providing easy access to hyper-targeted opportunities in minutes. The company asserts that its platform allows any business, regardless of its size, to sign up, post its partnership requirements, and explore opportunities for free. The company's portal allows users to request a 1-hour 'Discovery' call with a potential partner when the said user spots a relevant opportunity. Findr argues that it has made 'Discovery' for free for the first few months to build its user base. The company has onboarded 140 business users ranging from early-stage to global brands such as Mastercard, Uber and Visa since November 2020. Findr has featured in Forbes for helping businesses navigate COVID-19. The company will use the investment to develop two new price plans – Unlimited and Enterprise, introduce new platform features, hire a machine learning expert, and undertake digital activity to grow its user base.
days to go:
Expired
investment:
£396,288
A P2P lender for short-term borrowers focused on providing affordable, flexible and ethical loans. Welendus has full FCA authorisation and there are over 18,000 users on the platform with more than 900 loans issued. Investment is sought to expand the team with new operational members and grow the service with the use of viral marketing and referrals. The company is seeking more IP applications and to develop the service with new functionalities.
days to go:
Expired
investment:
£939,104
MergerLinks is a platform where global dealmakers can connect and identify with transaction counterparts based on their relationships and credentials. The company collates proprietary and public transactions data and assembles it into an information tool. MergerLinks also forms an ecosystem where clients can easily access advisory services. This is done by contacting and identifying people with the right skill set and network. Most of the revenue generated by MergerLinks comes from the sale of B2B subscriptions to a range of connectivity and data tools. With the proceeds, the company will market its premium subscriptions, build the network of content distribution partners, and build Customer Success function.
days to go:
Expired
investment:
£239,270
Wedding Planner is an online wedding-planning marketplace that provides an easy way to plan and book a wedding. Around 20,000 couples are using this platform to plan their dream weddings. Besides being a pre-COVID profitable business in the UK, it is the UK's number one ranked site for 'Wedding Planner' as per Google. The website has been created by combining a digital wedding booking system, curated venues, planning tools, and supplier search options. The platform generates 8,500+ leads for venues and suppliers per quarter and has a registered base of 3,000+ venues and other suppliers. With the investment, the company will use 25% to update their booking system catering to couples and suppliers, 12% in creating new and tested standardised contract templates between the couple and the supplier, 13% in developing a partnership with a wedding insurance provider, 30% as substitution funds for supplier and venue subscriptions frozen during COVID-19, 13% in continuing the platform's growth in Sweden, and 7% in costs associated with fund-raising.
days to go:
Expired
investment:
£25,010
Avida Global (AG) is a Business-to-Business (B2B) producer of high-quality medicinal cannabis oils and derivatives for the global medical, well-being and cosmeceutical markets. The company has a cultivation and processing facility in North-East Colombia. It asserts that the therapeutic properties of the cannabis plant has driven 53 countries to legalise its use, with more to follow. AG seeks to capture this demand and become a contender in the medicinal cannabis market that is expected to soar from $33.1 billion to $84.0 billion by 2028. The company has received regulatory approvals for initial non-psychoactive cannabis cultivation, manufacturing, and export licences in 2019. It is working on a partnership with a medicinal cannabis prescriber through doctors and clinics for the supply of medicinal cannabis strains in the UK. The company will use 40% of the investment to drive revenue growth, 25% as capital expenses, and 35% as additional operating expenses.
days to go:
Expired
investment:
£1,646,249
